Renovaro (NASDAQ:RENB) Posts Earnings Results

Renovaro (NASDAQ:RENB) posted its quarterly earnings results on Wednesday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.

Renovaro Price Performance

NASDAQ:RENB traded up $0.05 during mid-day trading on Wednesday, reaching $0.86. The stock had a trading volume of 673,546 shares, compared to its average volume of 1,048,723. The business’s 50 day moving average is $0.96 and its 200 day moving average is $0.76. Renovaro has a fifty-two week low of $0.40 and a fifty-two week high of $3.38. The stock has a market cap of $136.50 million, a P/E ratio of -0.90 and a beta of 0.63.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.